[Skip to Navigation]
Sign In
Original Investigation
October 17, 2023

Effects of the Million Hearts Model on Myocardial Infarctions, Strokes, and Medicare Spending: A Randomized Clinical Trial

Author Affiliations
  • 1Mathematica, Washington, DC
  • 2Mathematica, Cambridge, Massachusetts
  • 3Department of Medicine, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania
  • 4RAND Corporation, Santa Monica, California
  • 5Mathematica, Oakland, California
  • 6University of Colorado School of Medicine, Denver
  • 7Mathematica, Chicago, Illinois
  • 8RAND Corporation, Arlington, Virginia
  • 9Center for Medicare and Medicaid Innovation, Centers for Medicare & Medicaid Services, Baltimore, Maryland
JAMA. 2023;330(15):1437-1447. doi:10.1001/jama.2023.19597
Visual Abstract. Effects of the Million Hearts Model on Myocardial Infarctions, Strokes, and Medicare Spending
Effects of the Million Hearts Model on Myocardial Infarctions, Strokes, and Medicare Spending
Key Points

Question  Did the Million Hearts Model, which encouraged and paid for cardiovascular risk assessment and reduction, reduce the incidence of first-time myocardial infarctions and strokes or Medicare spending among Medicare beneficiaries aged 40 to 79 years?

Findings  The model reduced the probability of a first-time myocardial infarction or stroke over 5 years by 0.3 percentage points among people at high or medium risk for these events, without statistically significant changes in Medicare spending.

Meaning  The commitment of health care organizations to cardiovascular risk assessment and follow-up, coupled with payments for risk assessment and reduction, reduced myocardial infarction and stroke rates. Results support guideline recommendations for cardiovascular risk assessment.

Abstract

Importance  The Million Hearts Model paid health care organizations to assess and reduce cardiovascular disease (CVD) risk. Model effects on long-term outcomes are unknown.

Objective  To estimate model effects on first-time myocardial infarctions (MIs) and strokes and Medicare spending over a period up to 5 years.

Design, Setting, and Participants  This pragmatic cluster-randomized trial ran from 2017 to 2021, with organizations assigned to a model intervention group or standard care control group. Randomized organizations included 516 US-based primary care and specialty practices, health centers, and hospital-based outpatient clinics participating voluntarily. Of these organizations, 342 entered patients into the study population, which included Medicare fee-for-service beneficiaries aged 40 to 79 years with no previous MI or stroke and with high or medium CVD risk (a 10-year predicted probability of MI or stroke [ie, CVD risk score] ≥15%) in 2017-2018.

Intervention  Organizations agreed to perform guideline-concordant care, including routine CVD risk assessment and cardiovascular care management for high-risk patients. The Centers for Medicare & Medicaid Services paid organizations to calculate CVD risk scores for Medicare fee-for-service beneficiaries. CMS further rewarded organizations for reducing risk among high-risk beneficiaries (CVD risk score ≥30%).

Main Outcomes and Measures  Outcomes included first-time CVD events (MIs, strokes, and transient ischemic attacks) identified in Medicare claims, combined first-time CVD events from claims and CVD deaths (coronary heart disease or cerebrovascular disease deaths) identified using the National Death Index, and Medicare Parts A and B spending for CVD events and overall. Outcomes were measured through 2021.

Results  High- and medium-risk model intervention beneficiaries (n = 130 578) and standard care control beneficiaries (n = 88 286) were similar in age (median age, 72-73 y), sex (58%-59% men), race (7%-8% Black), and baseline CVD risk score (median, 24%). The probability of a first-time CVD event within 5 years was 0.3 percentage points lower for intervention beneficiaries than control beneficiaries (3.3% relative effect; adjusted hazard ratio [HR], 0.97 [90% CI, 0.93-1.00]; P = .09). The 5-year probability of combined first-time CVD events and CVD deaths was 0.4 percentage points lower in the intervention group (4.2% relative effect; HR, 0.96 [90% CI, 0.93-0.99]; P = .02). Medicare spending for CVD events was similar between the groups (effect estimate, −$1.83 per beneficiary per month [90% CI, −$3.97 to −$0.30]; P = .16), as was overall Medicare spending including model payments (effect estimate, $2.11 per beneficiary per month [90% CI, −$16.66 to $20.89]; P = .85).

Conclusions and Relevance  The Million Hearts Model, which encouraged and paid for CVD risk assessment and reduction, reduced first-time MIs and strokes. Results support guidelines to use risk scores for CVD primary prevention.

Trial Registration  ClinicalTrials.gov Identifier: NCT04047147

Add or change institution
×